Inhaled corticosteroids in COPD: A light at the end of the tunnel?

Thorax

Volumn 60, Issue 12, 2005, Pages 977-978

  Wedzicha, J A ^a   Seemungal, T A R ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID;

CANCER MORTALITY; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; EDITORIAL; HEALTH STATUS; HUMAN; HYPERACTIVITY; LUNG CANCER; LUNG FUNCTION; MEDICAL RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; SMOKING CESSATION; TIME SERIES ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; HUMANS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 28244487752     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2005.053454     Document Type: Editorial

References (27)

1. Murray CJL, Lopez AD. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997;349:1436-42.
2. 1. The Lung Health Study. JAMA 1994;16:1539-41.
3. Anthonisen NR, Skeans MA, Wise RA, et al. Lung Health Study Research Group. The effects of a smoking cessation intervention on 14. 5-year mortality: a randomized clinical trial, Ann Intern Med 2005;142:233-9.
4. Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxaemic chronic obstructive lung disease. Ann Intern Med 1980;93:391-8.
5. Medical Research Council Working Parry. Long-term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981;i:681-6.
6. Seemungal TAR, Donaldson GC, Paul EA, et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1418-22.
7. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320:1297-303.
8. Spencer S, Calverley PMA, Burge PS, et al. Impact or preventing exacerbations on deterioration of health status in COPD. Eur Respir J 2004;23:1-5.
9. Donaldson GC, Seemungal TAR, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847-52.
10. 1 decline in smokers but not ex-smokers with mild chronic obstructive pulmonary disease: results from the Lung Health Study. Am J Respir Crit Care Med 2001;164:358-64.
11. Soler-Cataluña JJ, Martinez-Garcia MA, Roman Sanchez P, et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005;60:925-31.
12. Sin DD, Wu L, Anderson JA, et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005;60:992-7.
13. Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343:1902-9.
14. Vestbo J, Sorenson T, Lange P, et al. Long term effect of inhaled budesonide in mild and moderate mild chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999;353:1819-23.
15. Pauwels RA, Lofdahl C-G, Laitinen LA, et al. Long term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease. N Engl J Med 1999;340:1819-23.
16. Calverley PMA, Pauwels R, Vestbo J, for the Tristan Study Group, et al. Combined Salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-56.
17. Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-8.
18. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81.
19. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomised placebo-controlled trials. Am J Med 2002;113:59-65.
20. Sutherland ER, Allmers H, Ayas NT, et al. Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax 2003;58:937-41.
21. Watson L, Vonk JM, Lofdahl CG, et al. Predictors of lung function and its decline in mild to moderate COPD in association with gender: results from the EUROSCOP study. Respir Med 2005 September 29 (epub ahead of print).
22. Kanner RE, Connett JE, Altose MD, et al. Gender difference in airway hyperresponsiveness in smokers and mild COPD. The Lung Health Study. Am J Respir Crit Care Med 1994;150:956-61.
23. Calverley PMA, Spencer S, Burge, et al, on behalf of the ISOLDE study group. Withdrawing from treatment as an outcome in chronic obstructive pulmonary disease. Chest 2003;124:1350-6.
24. Wedzicha JA. Inhaled corticosteroids in COPD: awaiting controlled trials. Thorax 1993;48:305-7.
25. Wedzicha JA, Seemungal TAR, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000;84:210-5.
26. Donaldson GC, Seemungal TAR, Patel IS, et al. Airway and systemic inflammation and decline in lung function in chronic obstructive pulmonary disease. Chest 2005(in press).
27. Vestbo J, TORCH Study Group. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur Respir J 2004;24:206-10.